1. Medtech Insight
  2. >>Business
  3. >>Deals

Super-Sized Medtech Rounds Scarce, But Growing

The number of big medtech venture rounds, those worth at least $50 million, has decreased and plateaued over the past couple of years, but the overall dollars brought in by those scarce deals notably increased in 2015. And a few lucky medtech firms managed to grab more than $100 million from single fundraises last year.

The median value of super-sized medtech financings hit a high of $100 million in 2015. Five companies closed on venture deals worth $50 million or more, and three of those five raised at least $100 million, according to Informa’s Strategic Transactions. (See Exhibit 1.) Combined, those 2015 deals had a total value of $551 million. By comparison in 2011, when the total raised by super-sized deals peaked, seven deals yielded $566 million, but none were worth ≥$100 million, and the median value per round was $65 million. In 2014 when the least was raised through super-raises, five rounds yielded $385 million, for a median value of a relatively low $56 million per deal.

These medtech numbers have all been dwarfed of course by biotech, which saw in 2015 a full year of huge...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Siemens Healthineers Mitigates Headwinds With ‘Value-Add Structural Changes’

 
• By Natasha Barrow

Siemens Healthineers anticipates €400m-€500m tariff impact by 2026 but says it will mitigate losses through structural changes and pricing. Despite a revenue decline in diagnostics due to China’s VBP, diagnostics transformation activities, including cutting product, were “successful."

Olympus, Revival Co-Found Swan In $458M Deal, Face Tech and Regulatory Hurdles

 
• By Marion Webb

Olympus and Revival Healthcare Capital have launched Swan Endosurgical in a $458m milestone-based joint venture to develop a robotic platform for endoluminal surgery. The deal combines Olympus’ GI expertise with Revival’s start-up model, but will face technical and regulatory hurdles.

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 
• By Natasha Barrow

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

Medtech M&A Resurges: How To Define Startup Exit Strategy

 
• By Natasha Barrow

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.

More from Business

FDA’s Small Business Eligibility Process Gets Update Before New Fiscal Year

 
• By Elizabeth Orr

The US FDA has updated its guidance document on small business eligibility determinations for medical device firms. Industry observers urge companies to ask for the status early to avoid any potential hold-ups.

Thermo Fisher Margins Feel The Weight Of Tariffs Even As China Trade Pressures Ease In Q2

 
• By Shubham Singh

Thermo Fisher said the year-over-year impact of tariffs and related effects represented a 5% headwind to adjusted operating income and reduced reported margins by 140 basis points in the second quarter.

NIH-Backed Scanner Opens New Frontier For Understanding The Human Brain

 
• By Brian Bossetta

A new MRI scanner developed by a team of scientists working with the National Institutes of Health marks a milestone in understanding the complexities of the human brain. Andrea Beckel-Mitchener with the NIH Brain Initiative discusses the significance of this potentially game-changing device.